Table 2.

Relations between FGF-23 concentrations and different combinations of anti-diabetes therapy

	Yes	No	P-value
SGLT-2 inhibitor only (n = 27)	71 (61–94)	75 (58–91)	0.89
GLP-1 analogue only (n = 20)	68 (55–87)	81 (60–98)	0.04*
SGLT-2 inhibitor + GLP-1 analogue (n = 16)	74 (57–91)	74 (61–92)	0.86
Insulin only (n = 67)	68 (55–86)	75 (60–94)	0.03
Insulin + SGLT-2 inhibitor (n = 28)	75 (62–90)	74 (57–91)	0.62
Insulin + GLP-1 analogue (n = 40)	72 (58–88)	83 (60–99)	0.04
Insulin + SGLT-2 inhibitor + GLP-1 analogue (n = 11)	74 (58–93)	75 (58–91)	0.76

Data presented as median (Q1–Q3). GLP-1 glucagon like peptide-1, SGLT-2 sodium-glucose cotransporter 2. Significant differences indicated in bold.